As per Future Market Insights (FMI) latest analysis, the global cell culture market is projected to total USD 44,593.1 million by 2034, up from USD 27,911.3 million in 2024. It will exhibit a CAGR of 4.7% from 2024 to 2034.
Several factors are set to fuel growth of the cell culture during the assessment period. These include escalating demand for biopharmaceuticals, advances in stem cell culture techniques, and growing interest in personalized medicines.
Cell cultures are becoming key for the production of biopharmaceuticals like monoclonal antibodies and insulin as well as vaccines. Thus, surging need for these biopharmaceuticals due to high chronic disease prevalence is set to propel cell culture demand globally.
Personalized medicine is a recent emerging medical practice that considers an individual’s genetic profile to diagnose, treat, and prevent disease. Researchers are creating customized and complex disease models of patients’ cells using cell culture, allowing an in-depth analysis of the patient’s unique genetic makeup. This paves the way for developing more accurate drug testing models, increasing precision in drug development, reducing side effects, and increasing the probability of successful treatment.
With growing healthcare awareness and demand for vaccines, the market is projected to experience steady growth during the forecast period. Government support for drug discovery is also contributing to market growth. For instance, the Union Government of India launched the Drug Discovery Hackathon “Nishank” in July 2020, supported by various departments and market players.
As the role of different biomarkers becomes evident in disease etiology, numerous pharmaceutical and biopharma giants are increasing their research and development efforts towards personalized medicine. The oncology market has emerged as the most lucrative area for personalized medicine due to disease heterogeneity and the increasing number of approved biomarkers.
Immunology and neurodegenerative diseases are other areas experiencing increased research activity in personalized medicine. Therefore, due to the rising demand for personalized medicine and the pivotal role served by cell culture in this area, the market for cell culture is growing.
Key Takeaways from the Market Study:
- The global market value is estimated to total USD 44,593.1 million in 2034.
- By phase, the commercial segment is projected to lead the market, growing at a CAGR of 3.9% during the forecast period.
- By end user, the biotechnology and pharmaceutical companies segment is set to grow at 6.0% CAGR through 2034.
- North America accounted for a prominent value share of 36.8% in 2023.
- The United States is set to record a CAGR of 3.0% through 2034.
- Revenue in China is poised to rise at 7.9% CAGR between 2024 and 2034.
“Researchers and biotechnologists are adopting sustainable and animal-free cell culture technologies. This transition aims to reduce reliance on animal-derived products and mitigate the environmental impact of cell culture processes.” – says a lead analyst of Future Market Insights (FMI).
Increased Market Attention: Delve into Detailed Trends and Analysis with Our Report!
Who is Winning?
Leading companies are implementing tactical approaches, such as mergers and acquisitions, business extensions, and new product creation, in order to broaden their range of offerings and fortify their position in the market. For instance,
- In July 2023, With GS-CHO cell lines, Lonza introduced the TheraPRO CHO Media System, a new platform for cell culture that streamlines procedures and maximizes output and protein quality.
- In June 2021, Bio-Rad Laboratories, Inc. collaborated with Seegene, Inc. for the clinical development and commercialization of molecular diagnostic tools for infectious diseases.
Key Companies Profiled:
- Thermo Fisher Scientific Inc.
- Merck KGaA (Sigma-Aldrich Co., LLC).
- Danaher Corporation (Cepheid)
- Agilent Technologies, Inc.
- Bio-Rad Laboratories
- STEMCELL Technologies
- Lonza AG
- Corning Incorporated
- Eppendorf AG
- FUJIFILM Irvine Scientific, Inc.
- Sartorius AG
- Getinge AB
- HiMedia Laboratories
- Cellexus
- Biospherix Ltd.
- PromoCell GmbH
- Bio-Techne Corporation
Key Market Segments:
By Product:
- Consumables
- Media
- Serum Containing Media
- Serum Free Media
- Protein Expression Media
- Stem Cell Media
- Hybridoma Media
- Primary Cell Media
- Insect Cell Media
- Immunology Media
- CHO Cell Culture Media
- HEK Media
- BHK Media
- Protein Free Media
- Chemically Defined Media
- Sera
- Fetal Bovine Sera (FBS)
- Adult Bovine Sera (ABS)
- Other Animal Sera
- Reagents
- Growth Factors
- Supplements
- Buffers & Chemicals
- Cell Dissociation Reagents
- Cryoprotective Agents
- Other Reagents
- Media
- Cell Lines
- CHO
- HEK
- Stem Cells
- Hematopoietic (Blood-Forming) Stem Cells (HSC)
- Skeletal Muscle Stem Cells
- Mesenchymal Stem Cells
- iPSCs
- Lymphocytes
- Dendritic Cells
- Pancreatic Islet Cells
- CAR-T Cells
- Equipment
- Supporting Equipment
- Filtration Systems
- Cell Counters
- Carbon Dioxide Incubators
- Centrifuges
- Autoclaves
- Microscopes
- Biosafety Cabinets
- Other Supporting Equipment
- Bioreactors
- Static Culture system
- Hollow Fiber Bioreactor System
- Stirred Bioreactor Systems
- Perfusion Bioreactor Systems
- Microcarrier Based Systems
- Suspension Culture Systems
- Storage Equipment
- Refrigerators & freezers
- Cryostorage Systems
- Other Equipment
- Cell Isolation System
- Automated Cell Processing Systems
- Cryopreservation Systems
- Cell Characterization & analysis systems
- Automated Filling & Packaging Systems
- Automated Liquid Handing Systems
- Supporting Equipment
- Cultureware
- Vessels
- Roller/Roux Bottles
- Cell Stacks
- Multiwell Plates
- Flasks
- Petri Dishes
- Accessories
- Vessels
By Application:
- Cell Therapy
- Gene therapy
- Protein Production
- Other Applications
By Phase:
- Clinical/Research & Development
- Research
- Pre-Clinical
- Clinical
- Commercial
By End User:
- Biotechnology and Pharmaceutical Companies
- Contract Research Development & Manufacturing Organizations (CDMO)
- Contract Research Organizations (CROs)
- Academic and Research Institutions
By Region:
- North America
- Latin America
- East Asia
- South Asia and Pacific
- Western Europe
- Eastern Europe
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
